CORPORATE PROFILE

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

If you are in the U.S., please click here for more information about Rubraca®

Our first product, Rubraca® (rucaparib) tablets, is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. In December 2016, Rubraca became the first PARP approved by the U.S. Food and Drug Administration (FDA) as monotherapy for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more prior chemotherapies.

Rucaparib is also being developed as maintenance treatment for advanced ovarian cancer in the ARIEL3 trial. Comprehensive data from the successful phase 3 ARIEL3 trial were presented at the European Society for Medical Oncology (ESMO) in September 2017 and subsequently published in *The Lancet* in an article titled, "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial." The phase 3 ARIEL3 trial evaluated rucaparib as a maintenance treatment in platinum-sensitive high-grade ovarian cancer patients with advanced ovarian, fallopian tube and primary peritoneal cancer. Based on these results, the Company is pursuing an expanded label to potentially help a broader population of women with platinum-sensitive, advanced ovarian cancer beyond the current Rubraca treatment indication.

In October 2017, Clovis submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Association (FDA) for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The sNDA submission is based on data from the Phase 3 ARIEL3 trial. Clovis' Marketing Authorization Application (MAA) for rucaparib to the European Medicines Agency for an ovarian cancer treatment indication is currently under review. Following a potential approval for the treatment indication, Clovis intends to submit a variation to the MAA for maintenance treatment.

Two additional ovarian cancer studies are ongoing or expected to begin enrolling patients before the end of 2017. The ARIEL4 confirmatory study in the treatment setting is currently enrolling relapsed ovarian cancer patients with BRCA mutations (inclusive of germline and/or somatic) who have failed two prior lines of therapy. The pivotal ATHENA study investigating combination switch maintenance following front-line platinum-based chemotherapy in ovarian cancer patients is expected to begin enrolling patients in the first half of 2018 and will evaluate rucaparib in combination with nivolumab. This study is part of a broad clinical collaboration with Bristol-Myers Squibb.

Our TRITON clinical development program, with two trials currently enrolling (TRITON2 and TRITON3), is evaluating rucaparib in patients with BRCA, ATM and other homologous recombination (HR) DNA-repair genes who have metastatic castration-resistant prostate cancer (mCRPC). Additionally, in Spring 2018, we are initiating a Phase 2 study of rucaparib in recurrent, metastatic bladder cancer in patients with locally advanced or metastatic urothelial carcinoma (ATLAS).

Exploratory studies in other tumor types are also underway.

By pursuing a thorough scientific understanding of rucaparib and sharing these insights with the clinical community, we hope to make contributions that move the entire field forward and help change the cancer treatment paradigm. We maintain worldwide rights to rucaparib.

Clovis Oncology's management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company's vision. Clovis is headquartered in Boulder, Colorado, with offices in San Francisco, California, and Cambridge, United Kingdom.